Clinical Trials Logo

PTCL-NOS clinical trials

View clinical trials related to PTCL-NOS.

Filter by:
  • None
  • Page 1

NCT ID: NCT04423926 Recruiting - AITL Clinical Trials

Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Start date: June 10, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The prognosis of PTCL (except early stage ALK+ ALCL) is dismal. Previous study showed that single agent lenalidomide showed promising therapeutic activity in patients with relapsed or refractory PTCL. The investigators therefore design this phase II study to investigate the safety and efficacy of lenalidomide in combination with CHOP in patients with treatment-naive PTCL.

NCT ID: NCT02223208 Active, not recruiting - Clinical trials for Peripheral T-cell Lymphomas (PTCL)

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

FIL_PTCL13
Start date: September 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study. 2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.